In the latest trading session,, 0.49 million Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) shares changed hands as the company’s beta touched 1.08. With the company’s most recent per share price at $8.42 changing hands around $0.03 or 0.30% at last look, the market valuation stands at $1.76B. BCRX’s current price is a discount, trading about -12.83% off its 52-week high of $9.50. The share price had its 52-week low at $4.11, which suggests the last value was 51.19% up since then. When we look at Biocryst Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 3.47 million shares, with the 3-month average coming to 3.47 million.
Analysts gave the Biocryst Pharmaceuticals Inc (BCRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.18. If we narrow down to specifics, the data shows that 0 out of 13 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended BCRX as a Hold, 11 felt it is a Buy and 0 rated the stock as Underweight.
Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) trade information
Instantly BCRX is in green as seen in intraday trades today. With action 11.76%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 11.91%, with the 5-day performance at 11.76% in the green. However, in the 30-day time frame, Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) is 7.48% up. Looking at the short shares, we see there were 20.44 million shares sold at short interest cover period of 6.59 days.
The consensus price target for the stock as assigned by Wall Street analysts is 16, meaning bulls need an upside of 47.38% from its recent market value. According to analyst projections, BCRX’s forecast low is 7 with 25 as the target high. To hit the forecast high, the stock’s price needs a -196.91% plunge from its current level, while the stock would need to tank 16.86% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 14.52%. The 2025 estimates are for Biocryst Pharmaceuticals Inc earnings to increase by 82.03%.
BCRX Dividends
Biocryst Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2025-Feb-23.
Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.15% of Biocryst Pharmaceuticals Inc shares while 81.13% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 82.07%. There are 81.13% institutions holding the Biocryst Pharmaceuticals Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 9.6676% of the shares, roughly 19.96 million BCRX shares worth $123.33 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.0926% or 18.77 million shares worth $116.0 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 6.5 shares estimated at $54.56 million under it, the former controlled 3.11% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.60% of the shares, roughly 5.43 shares worth around $45.57 million.
